Reviews/Perioperative Immunotherapy Solid Tumours/Adjuvant pembrolizumab in stage III melanoma
Melanoma · PERIO-MEL-02 · v2
The question is whether giving pembrolizumab after surgery, compared to a placebo, keeps patients with removed stage III melanoma free of their cancer coming back for longer. One large, rigorously designed trial of 1,019 patients, in which neither patients nor doctors knew who got the drug, found that the drug group went longer without recurrence than the placebo group [3]. The same trial was followed up and reported again at three, five and seven years, and the advantage held each time [6], [8], [15]. Internal re-analyses of the same patients pointed the same way [5], [9]. The panel treated this as very strong because the trial directly matches the claim in every respect; the one caveat is that all the evidence comes from this single trial rather than from a second, independent one.
The corpus contains the pivotal double-blind placebo-controlled phase 3 trial (EORTC 1325/KEYNOTE-054, N=1019) in which adjuvant pembrolizumab prolonged recurrence-free survival versus placebo at the primary analysis (hazard ratio 0.57, P<0.001) [3]. Follow-up readouts of the same trial confirmed the benefit at three years (hazard ratio 0.56; 3-year RFS 63.7% vs 44.1%) [6], [12], five years (hazard ratio 0.61; 55.4% vs 38.3%) [8] and seven years (hazard ratio 0.63; 50% vs 36%) [15]. Two secondary analyses of the same randomised population re-reported the primary hazard ratio of 0.56 [5], [9]. Direction, population, intervention, comparator and outcome match the claim exactly, and the effect was consistent across the AJCC substages the trial enrolled [15]. The contested point: The evidence does not divide on direction or magnitude, which are consistent across every readout. The only point of weakness the panel identifies is independence: [3], [5], [6], [8], [9], [12] and [15] are all sequential or secondary readouts of the same 1,019 patients, so there is no second, independent trial of pembrolizumab versus placebo in this setting.
All 27 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Perioperative Immunotherapy Solid Tumours, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
All included evidence derives from a single trial (EORTC 1325/KEYNOTE-054); [3], [5], [6], [8], [9], [12] and [15] are sequential readouts and secondary analyses of the same 1019 randomised patients, not independent replications. The claim's truth rests on one RCT.
RFS is a surrogate for overall survival. The claim is scoped to RFS so this does not contradict it, but the corpus provides no placebo-controlled OS benefit for pembrolizumab, and a real-world cohort could not demonstrate population-level survival improvement.
Where it remains uncertain. Every supporting item is a readout or secondary analysis of the same single trial [3], [5], [6], [8], [9], [12], [15], so the claim rests on one RCT with no independent replication in this corpus.
Aleatory
Recurrence-free survival is reported as rates and hazard ratios with confidence intervals [3], [8], [15]; individual recurrence timing is inherently random even within the treated population.
Epistemic
Every supporting item is the same trial read out serially or re-analysed [3], [5], [6], [8], [9], [12], [15]; no second pembrolizumab-versus-placebo RCT exists in the corpus.
Inferential
The claim is scoped to recurrence-free survival, but inferring patient benefit beyond recurrence requires an overall-survival link the corpus does not establish; a real-world cohort could not demonstrate population-level survival improvement [13].
The load-bearing papers from a corpus of 27, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary phase 3 RCT result establishing the RFS benefit of adjuvant pembrolizumab over placebo in resected stage III melanoma.
“pembrolizumab was associated with significantly longer recurrence-free survival than placebo in the overall intention-to-treat population (1-year rate of recurrence-free survival, 75.4% [95% confidence interval {CI}, 71.3 to 78.9] vs. 61.0% [95% CI, 56.5 to 65.1]; hazard ratio for recurrence or death, 0.57; 98.4% CI, 0.43 to 0.74; P<0.001)”
Panel auditInternal validity: high · scope of inference: Resected high-risk stage III melanoma treated with 1 year of adjuvant pembrolizumab.Key limitations: 15-month median follow-up · RFS not OS
Secondary analysis of the trial corroborating the magnitude of the RFS benefit.
“Consistent with the reported main analysis in the intent-to-treat population, RFS was longer in the pembrolizumab arm compared with the placebo arm (hazard ratio [HR], 0.56; 98.4% CI, 0.43-0.74) among patients who started treatment.”
Panel auditInternal validity: high · scope of inference: Resected high-risk stage III melanoma; primary focus is the irAE–RFS association.Key limitations: secondary analysis · irAE association uses non-randomised time-varying covariate
Confirms durability of the RFS benefit at 3-year median follow-up.
“Pembrolizumab (190 RFS events) compared with placebo (283 RFS events) resulted in prolonged RFS in the overall population (3-year RFS rate, 63.7% v 44.1% for pembrolizumab v placebo, respectively; HR, 0.56; 95% CI, 0.47 to 0.68)”
Panel auditInternal validity: high · scope of inference: Resected high-risk stage III melanoma, 3.05-year median follow-up.Key limitations: RFS not OS
3 of 27 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A definitive double-blind placebo-controlled phase 3 RCT met and sustained its RFS primary endpoint across seven years, carrying the claim at the Established tier despite reliance on a single trial.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No independent replication. The claim rests entirely on EORTC 1325/KEYNOTE-054; a second trial would establish that the effect is not specific to this trial's conduct or cohort [3], [15]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An independent double-blind placebo-controlled phase 3 RCT of adjuvant pembrolizumab versus placebo in resected stage III melanoma.
Open question: Does the recurrence-free survival benefit of adjuvant pembrolizumab replicate in an independent trial? Why it is still open: Every supporting item in the corpus is a readout or secondary analysis of the same 1,019 patients [3], [5], [6], [8], [9], [12], [15].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19